

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

PSN1

RRID:CVCL_1644

Type: Cell Line

Proper Citation

RRID:CVCL_1644

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1644

Proper Citation: RRID:CVCL_1644

Description: Cell line PSN1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:1764370](#), [PMID:3009377](#), [PMID:3778442](#), [PMID:11787853](#), [PMID:18380791](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Characteristics: Established from a frozen tumor that had been stored at -80 Celsius for 1.5 years and which has then been passaged into a nude mice., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PSN1

Synonyms: PSN-1

Cross References: BTO:BTO_0005179, CLO:CLO_0008512, EFO:EFO_0006739, CLDB:cl3949, CLDB:cl3950, AddexBio:C0018013/4990, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ATCC:CRL-3211, ATCC:CRM-CRL-3211, BioGRID_ORCS_Cell_line:483, BioSample:SAMN03481109, BioSample:SAMN10988384, cancercelllines:CVCL_1644, Cell_Model_Passport:SIDM00469, CGH-DB:182-1, CGH-DB:9281-4, ChEMBL-Cells:ChEMBL3307348, ChEMBL-Targets:ChEMBL614241, Cosmic:710867, Cosmic:716172, Cosmic:733176, Cosmic:808165, Cosmic:808504, Cosmic:910546, Cosmic:2434092, Cosmic-CLP:910546, DepMap:ACH-000320, ECACC:94060601, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910546, GEO:GSM206537, GEO:GSM887521, GEO:GSM888603, GEO:GSM1374836, GEO:GSM1670353, IARC_TP53:945, ICLC:HTL97008, LiGeA:CCLE_595, LINCS_LDP:LCL-1749, Pharmacodb:PSN1_1277_2019, PRIDE:PXD030304, Progenetix:CVCL_1644, PubChem_Cell_line:CVCL_1644, Wikidata:Q54948596

ID: CVCL_1644

Record Creation Time: 20220427T221444+0000

Record Last Update: 20260905T182143+0000

Ratings and Alerts

No rating or validation information has been found for PSN1.

No alerts have been found for PSN1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Miyahara S, et al. (2026) Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Scientific reports, 16(1).

Sekiguchi N, et al. (2026)

Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment response

. International journal of oncology, 68(3).

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. *Cell reports*, 45(5), 117314.

Manoukian P, et al. (2026) Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. *Cancer research*, 86(3), 571.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. *Cancer research*, 86(8), 1868.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. *Science advances*, 11(42), eadx0632.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. *Cancer letters*, 622, 217713.

Toure MA, et al. (2025) Targeted degradation of CDK9 potentially disrupts the MYC-regulated network. *Cell chemical biology*, 32(4), 542.

Maki R, et al. (2025) Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. *Annals of surgical oncology*, 32(9), 7025.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. *Cancer research*, OF1.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. *Cell reports*, 44(4), 115541.

Wittenzellner K, et al. (2025) Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. *JCI insight*, 10(13).

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. *Nature*.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. *Nature communications*, 16(1), 4866.

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. *Nature communications*, 16(1), 10733.

Hang H, et al. (2025) SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e10071.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. *Cancer research*, 85(18), 3540.